Cambridge Meditech agreement with Lantor (UK)

Embargoed for release at 07.00 hours 24 May 2011

IPSO VENTURES PLC

("IPSO" or the "Company")

CAMBRIDGE MEDITECH SIGNS AGREEMENT WITH LANTOR (UK)

IPSO Ventures plc (AIM: IPS), the technology commercialisation business, is pleased to announce that its wholly-owned subsidiary, Cambridge Meditech Limited ("Cambridge Meditech"), has signed an agreement with Lantor (UK) Limited ("Lantor") that will lead to the development of advanced wound healing products that are capable of detecting infection in wounds.

The novel, patented technology owned by Cambridge Meditech detects breaches in the body's natural immune system by measuring the presence and concentration of lysozyme in a wound. The advantages of this technology are that it is simple and robust, pathogen independent and only activates once the body's natural immune system has been breached.

The agreement gives Lantor access to the technology for an initial evaluation period of 12 months, with the option for a commercial licence at the end of this period. Should this option be exercised by Lantor, Cambridge Meditech will receive regular milestone payments and royalties from product sales.

Nick Rodgers, CEO of IPSO, said: "We are very excited to work with Lantor on the development of such a novel product. This is yet another example of how, by bringing together know-how and IP from various sources, we are able to develop technologies which are commercially relevant and address serious commercial needs."

Further information, please contact:

Company description

IPSO Ventures plc is a business creator and active investor in new technologies, principally in the renewable energy and healthcare sector. Its experienced management team focuses on adding commercial value to enable young companies to move forward rapidly.